Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUL 20 ... new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for injection) to treat patients with myelodysplastic syndromes (MDS). MDS is a ...
2009 AUG 17 ... research from the United States, "The nucleoside analogue 5-aza-2'-deoxycytidine (Decitabine, DAC) is one of several drugs in clinical use that inhibit DNA methyltransferases, ...
2009 SEP 21 ... According to recent research from the United States, "Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug ...
2009 JUL 6 ... suppressor genes by 5-azacytidine (Vidaza) and its congener 5-aza-2'-deoxycytidine (decitabine) has provided an alternate approach to cancer therapy. We have shown previously that ...
2009 JUL 13 ... progression. Furthermore, they found that by treating melanoma cells with a drug called decitabine, an inhibitor of DNA methylation, these genes could be reactivated....
2009 AUG 24 ... to CG antigen gene activation mediated by the DNA methyltransferase inhibitor decitabine. To account for these findings, we examined DNA methylation at CG antigen gene promoters ...
2009 JUN 29 ... "Currently, effective DNA methylation inhibitors are mainly limited to decitabine and 5-azacytidine, which still show unfavorable toxicity profiles in the clinical ...
2009 NOV 1 ... we describe a 64-year-old male with acute fibrinous and organizing pneumonia caused by decitabine," wrote T.S. Vasu and colleagues, Thomas Jefferson University. The ...
2009 JUN 29 ... leukemia are presented in the report 'The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid ...
2009 JUN 29 ... and AIM1 correlated with low expression of the transcripts. Reversal of methylation by Decitabine induced expression of PRDM1 and cell death," wrote J. Iqbal and colleagues, University ...
2009 OCT 19 ... associated with a low-response rate and significant nonhematologic toxicity. Both decitabine and gemtuzumab ozogamicin have activity in AML as single agents and can be administered ...
2009 AUG 3 ... "Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard of care for the treatment of the myelodysplastic syndrome, a deadly ...
2009 JUN 22 ... According to a study from Umea, Sweden, "Decitabine (also referred to as 5-aza-2'-deoxycytidine) is a drug that has recently been approved ...
2009 JUL 20 ... report. "Thirty-one patients with refractory malignancies received decitabine 2.5 to 10 mg/m(2) on days 1 to 5, and 8 to 12 or 15 to 20 mg/m(2) on days 1 to 5. Tumor ...
2009 JUL 27 ... According to recent research from the United States, "Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is ...
2009 NOV 23 ... Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine Keywords: Sunesis Pharmaceuticals, Inc., Cancer, Oncology, ...
2009 AUG 10 ... to the development, manufacture, commercialization and distribution of Dacogen® (decitabine) for Injection. The Company recognizes royalty revenue when it is received. ...
2009 NOV 9 ... to the development, manufacture, commercialization and distribution of Dacogen® (decitabine) for Injection. The Company generally recognizes royalty revenue when it is received. ...
2009 NOV 2 ... In the updated NCCN Guidelines, 5-azacytidine (Vidaza®, Celgene Corporation) and decitabine (Dacogen®, Eisai Inc.), have been added as low intensity treatment options and ...
